Michael J Pontecorvo

Summary

Publications

  1. pmc PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders
    Andrew Siderowf
    Banner Sun Health Research Institute, Sun City, AZ 10515W Santa Fe Dr, USA
    BMC Neurol 14:79. 2014
  2. pmc PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease
    Michael J Pontecorvo
    Avid Radiopharmaceuticals, 3711 Market Street, 7th Floor, Philadelphia, PA 19104, USA
    Alzheimers Res Ther 3:11. 2011
  3. ncbi request reprint Use of florbetapir-PET for imaging beta-amyloid pathology
    Christopher M Clark
    Avid Radiopharmaceuticals, Philadelphia, Pennsylvania, USA
    JAMA 305:275-83. 2011
  4. ncbi request reprint Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent
    John Lister-James
    Avid Radiopharmaceuticals, Philadelphia, PA
    Semin Nucl Med 41:300-4. 2011

Collaborators

  • Mark A Mintun
  • Daniel M Skovronsky
  • Andrew Siderowf
  • Marwan N Sabbagh
  • Abhinay D Joshi
  • Franz Hefti
  • Hank F Kung
  • Christopher M Clark
  • Alan P Carpenter
  • John Lister-James
  • Carolyn Liebsack
  • Holly A Shill
  • Ming Lu
  • Douglas Galasko
  • Charles H Adler
  • Anupa Arora
  • Thomas G Beach
  • Warren B Bilker
  • Michael J Krautkramer
  • R Edward Coleman
  • Seok Rye Choi
  • Wei Zhang
  • Adam S Fleisher
  • Julie A Schneider
  • P Eric M Reiman
  • Matthew L Flitter
  • Geoff Golding
  • Chris Clark
  • Paul Kennedy
  • P Murali Doraiswamy
  • Simone P Zehntner
  • Barry J Bedell
  • Zhiping Zhuang
  • Nathaniel Lim
  • Tyler E Benedum
  • Carl H Sadowsky
  • Eric P Reiman

Detail Information

Publications4

  1. pmc PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders
    Andrew Siderowf
    Banner Sun Health Research Institute, Sun City, AZ 10515W Santa Fe Dr, USA
    BMC Neurol 14:79. 2014
    ....
  2. pmc PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease
    Michael J Pontecorvo
    Avid Radiopharmaceuticals, 3711 Market Street, 7th Floor, Philadelphia, PA 19104, USA
    Alzheimers Res Ther 3:11. 2011
    ..Although large longitudinal studies like the ongoing ADNI trial will be required for definitive evaluation, present data suggest that PET amyloid imaging has the potential to promote earlier and more specific diagnosis of dementia...
  3. ncbi request reprint Use of florbetapir-PET for imaging beta-amyloid pathology
    Christopher M Clark
    Avid Radiopharmaceuticals, Philadelphia, Pennsylvania, USA
    JAMA 305:275-83. 2011
    ..The ability to identify and quantify brain β-amyloid could increase the accuracy of a clinical diagnosis of Alzheimer disease...
  4. ncbi request reprint Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent
    John Lister-James
    Avid Radiopharmaceuticals, Philadelphia, PA
    Semin Nucl Med 41:300-4. 2011
    ..Clinical studies have demonstrated a clear correlation between in vivo PET imaging with florbetapir F-18 and postmortem histopathologic quantitation of β-amyloid in the brain...